Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CCQWD
ADC Name
MM-310
Synonyms
MM 310; MM-310; MM310
   Click to Show/Hide
Organization
Merrimack Pharmaceuticals, Inc.
Drug Status
Phase 1
Antibody Name
Undisclosed
Antigen Name
Ephrin type-A receptor 2 (EPHA2)
  Antigen Info 
Payload Name
Docetaxel
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
Indication Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 New Drug Application Approved
Endometrial cancer
1 Trials
Trial ID
NCT03076372
Head and neck cancer
1 Trials
Trial ID
NCT03076372
Ovarian cancer
1 Trials
Trial ID
NCT03076372
Prostate cancer
1 Trials
Trial ID
NCT03076372
Sarcoma
1 Trials
Trial ID
NCT03076372
Unspecific solid tumor
1 Trials
Trial ID
NCT03076372
Urothelial cancer
1 Trials
Trial ID
NCT03076372
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03076372
PHASE1
A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
Undisclosed  NCT03076372
Phase 1
A phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Key eligibility: Adults (≥18) with specified advanced solid tumors (including urothelial, G/GEJ/E, SCCHN, ovarian, PDAC, etc.), ECOG 0-1, adequate organ function (ANC >1,500/ul, platelets >100,000/ul, bilirubin ≤ULN). Major exclusions: prior docetaxel (6 months), active bleeding disorders, CNS metastases, strong CYP3A inhibitors use, grade ≥2 neuropathy, or anticoagulation therapy (except aspirin). Requires accessible tumor for biopsy and recovery from prior treatments (CTCAE v4.03 grade ≤1).

   Click to Show/Hide
Administration Dosage
MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
Related Clinical Trial
NCT Number NCT03076372  Clinical Status PHASE1
Clinical Description A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
Primary Endpoint
Primary objective is to determine the MTD of MM-310 monotherapy administered every 3 weeks in metastatic solid tumor patients over an 18-month evaluation period.
Other Endpoint
Secondary endpoints include serum drug level analysis, AE assessment (NCI-CTCAE v4.03), immunogenicity (anti-drug antibodies), and efficacy measures (ORR/DCR by RECIST v1.1, PFS) all monitored over 18 months.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT03076372  Clinical Status Phase 1
Clinical Description A phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.
References
Ref 1 A Study Evaluating MM-310 in Patients With Solid Tumors
Ref 2 A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors